Clinical Policy: Granisetron (Sancuso, Sustol)
Defines medical necessity criteria, prior-authorization and continuation requirements, dosing limits, covered indications (chemotherapy-, radiation-, and postoperative-induced nausea/vomiting), product-specific age limits, and state-specific step-therapy/redirection exceptions for granisetron products across commercial, HIM, and Medicaid lines.
Clarified age requirement for Sancuso or Sustol (applies to those products only).
Allowed bypassing redirection (step therapy) for states with regulations against step therapy in certain oncology settings; Appendix E lists applicable states.
Modified PONV approval duration to 'one time dose' and removed inactive HCPCS code J3490.
Routine annual updates to references and appendices; no significant clinical changes reported.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.